肿瘤转移与获得性耐药的高度关联是导致肺癌患者治疗失败的最主要原因。转录因子Twist1在促进肿瘤转移，增强化疗抵抗性方面发挥了重要功能。在前期工作中我们鉴定了Twist1蛋白的SUMO修饰及其位点，并发现化疗药物顺铂对其具有特异性诱导作用，且Twist1的SUMO修饰能够显著增强肿瘤细胞耐药性。通过COSMIC数据库筛查发现临床肺癌患者中存在具有高SUMO修饰能力的Twist1天然突变体。在前期工作的基础上，本项目将深入研究Twist1蛋白SUMO修饰在非小细胞肺癌耐药性和肿瘤转移方面的生物学功能，阐明其分子机制，并结合临床样本评估SUMO-Twist1潜在的临床应用价值，初步探寻以此为靶点的干预策略，旨为临床逆转和预防耐药提供新的治疗靶点。

The high correlation between tumor metastasis and acquired drug-resistance is the main cause of treatment failure in patients with lung cancer. Transcription factor Twist1 plays a crucial role in promoting tumor metastasis and chemoresistance. In the previous work, we identified the SUMOylation of Twist1 and its site, and found that cisplatin could specifically induce the SUMOylation of Twist1, moreover, the SUMOylation of Twist1 significantly enhanced the drug resistance of tumor cells. COSMIC database screening revealled that native mutants of Twist1 with high SUMOylation capacity present in clinical lung cancer patients. On the basis of previous works, this project will further explore the biological function of Twist1 SUMOylation in drug resistance and tumor metastasis of non-small cell lung cancer, elucidate its molecular mechanism, and screen a large number of clinical samples to assess the potential value in clinical lung cancer therapy. The aim of this study is to provide new therapeutic targets for clinical reversal and prevention of drug resistance.